Trial · NCT02489227
Adverse events162
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 162
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Treatment Period 1: CHS-1420 | 24 | 274 | 24 |
| other | Nasopharyngitis | Infections and infestations | Treatment Period 1: Humira (Adalimumab) | 24 | 271 | 24 |
| other | Nasopharyngitis | Infections and infestations | Treatment Period 2: CHS-1420/CHS-1420 | 0 | 255 | 0 |
| other | Nasopharyngitis | Infections and infestations | Treatment Period 2: Humira/CHS-1420 | 0 | 126 | 0 |
| other | Nasopharyngitis | Infections and infestations | Teatment Period 2: Humira/Humira | 0 | 130 | 0 |
| other | Nasopharyngitis | Infections and infestations | Treatment Period 3: Open Label CHS-1420 Extension | 0 | 474 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 1: CHS-1420 | 17 | 274 | 17 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 1: Humira (Adalimumab) | 14 | 271 | 14 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 2: CHS-1420/CHS-1420 | 0 | 255 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 2: Humira/CHS-1420 | 0 | 126 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Teatment Period 2: Humira/Humira | 0 | 130 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Period 3: Open Label CHS-1420 Extension | 0 | 474 | 0 |
| serious | Acute Myocardial Infarction | Cardiac disorders | Treatment Period 1: CHS-1420 | 1 | 274 | 1 |
| serious | Acute Myocardial Infarction | Cardiac disorders | Treatment Period 1: Humira (Adalimumab) | 0 | 271 | 0 |
| serious | Acute Myocardial Infarction | Cardiac disorders | Treatment Period 2: CHS-1420/CHS-1420 | 0 | 255 | 0 |
| serious | Acute Myocardial Infarction | Cardiac disorders | Treatment Period 2: Humira/CHS-1420 | 0 | 126 | 0 |
| serious | Acute Myocardial Infarction | Cardiac disorders | Teatment Period 2: Humira/Humira | 0 | 130 | 0 |
| serious | Acute Myocardial Infarction | Cardiac disorders | Treatment Period 3: Open Label CHS-1420 Extension | 0 | 474 | 0 |
| serious | Diarrhea | Gastrointestinal disorders | Treatment Period 1: CHS-1420 | 0 | 274 | 0 |
| serious | Diarrhea | Gastrointestinal disorders | Treatment Period 1: Humira (Adalimumab) | 1 | 271 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02489227/events